Parexel Launched Integrated Business Model
The company debuted its new service model to streamline clinical trial support for biopharmaceutical clients.
Updated on Sept. 23, 2026 in Healthcare
Live Poll
Do you trust that new technology-driven business models improve the efficiency of professional services?
Parexel has introduced its FSP Integrated Solutions model to unify functional service provider offerings into a single delivery system. The model aims to support increasingly complex development programs with access to a massive pool of specialized talent.
Why it matters
Biopharmaceutical companies face significant pressure to boost R&D productivity and navigate increasingly complex development cycles. By consolidating support functions, Parexel intends to help these firms better manage their product lifecycle activities.
The new model provides access to over 8,000 FSP resources drawn from a global workforce exceeding 22,000 employees. These operations build upon the firm's 40 years of company history.
The players
Parexel
Headquartered in Raleigh, this global clinical research organization provides comprehensive services to the biopharmaceutical industry.
Sanjay Vyas
He serves as the newly appointed President of Integrated Solutions, Clinical Logistics & Managing Director India.
The details
The model leverages proprietary ParexelAI technology to provide tailored support for clinical, data management, biometrics, regulatory, and safety functions. Raleigh-based clients and global partners can now configure service solutions based on the specific scope and duration of their research programs.
Timeline
September 23, 2026: Parexel officially announced the launch of the FSP Integrated Solutions model.
Market Landscape
The launch of this integrated delivery model directly follows a pattern set by the industry-wide trend of biopharmaceutical R&D productivity challenges. This consolidation positions the company to capture larger market share by streamlining complex outsourced research functions for clients.
Biopharmaceutical companies working with the firm can expect more customizable service configurations for their ongoing clinical trials. These structural changes are designed to reduce administrative overhead and accelerate project timelines for drug development.
The takeaway
The move underscores a shift toward centralized, AI-driven outsourcing models in global clinical research. Companies looking to optimize their clinical operations may benefit from evaluating how unified service delivery impacts their own R&D speed and resource allocation.
Further reading
For more information on the evolving clinical trial sector, visit Healthcare.
More information
Learn more about the firm's capabilities on the Parexel official website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that new technology-driven business models improve the efficiency of professional services?
